Literature DB >> 1880231

Pharmacokinetics of ceftriaxone in liver-transplant recipients.

A Toth1, H Y Abdallah, R Venkataramanan, L Teperman, G Halsf, M Rabinovitch, G J Burckart, T E Starzl.   

Abstract

The disposition of ceftriaxone was studied after a single 2 g intravenous dose in seven patients 3 to 5 days after liver transplantation. Ceftriaxone concentrations in plasma, urine, and bile were measured by HPLC, and plasma protein binding was determined by equilibrium dialysis. Plasma protein binding was nonlinear, and the unbound fraction varied between 0.05 and 0.56. Both capacity and affinity were markedly different from reported values for normal subjects. The pharmacokinetic parameters obtained were: total body clearance (TBC), 11.2 +/- 7.8 mL/hr/kg total and 44.8 +/- 29.1 mL/hr/kg unbound; volume of distribution (V(area)), 224 +/- 76 mL/kg total and 767 +/- 432 mL/kg unbound; steady-state volume of distribution (Vss), 212 +/- 68 mL/kg total and 651 +/- 368 mL/kg unbound; terminal disposition half-life (t1/2), 21.6 +/- 14.3 hour total and 16.3 +/- 11.1 hour unbound. TBC for both total and free drug was considerably lower than literature values for normal subjects. V(area) for total drug was greater than normal, whereas the corresponding value for free drug was smaller than normal. The plasma ceftriaxone concentrations at 12 and 24 hours were above the reported minimum inhibitory concentration (MIC). The fraction of the administered dose excreted in urine over 24 hours was 38 +/- 29% and did not differ markedly from that reported for normal subjects. Less than 2% of the administered dose was excreted in 24-hour bile; however, biliary concentrations were always above MIC. Ceftriaxone can be administered once or twice daily at a dose of 2 g/day for prophylaxis in liver transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1880231      PMCID: PMC3216053          DOI: 10.1002/j.1552-4604.1991.tb03767.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

1.  Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination.

Authors:  J J Coffey; F J Bullock; P T Schoenemann
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

2.  Single-dose ceftriaxone kinetics in liver insufficiency.

Authors:  K Stoeckel; H Tuerk; V Trueb; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

3.  Pharmacokinetics of cefotaxime in normal human volunteers.

Authors:  F Esmieu; J Guibert; H C Rosenkilde; I Ho; A Le Go
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  Pharmacokinetics of the third-generation cephalosporins.

Authors:  S M Harding
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

Review 5.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

6.  Clinical study of Rocephin, a 3d generation cephalosporin, in various septicaemias.

Authors:  V Ghosen; R Chamali; O Bar-Moshe; P Stenier
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

7.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

8.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

9.  Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

Authors:  W L Hayton; R Schandlik; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

View more
  6 in total

1.  Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves.

Authors:  Y G Pawar; S K Sharma
Journal:  Vet Res Commun       Date:  2007-07-03       Impact factor: 2.459

2.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

3.  Cefpiramide kinetics and plasma protein binding in cholestasis.

Authors:  F Demontes-Mainard; G Vinçon; L Labat; M Amouretti; J Necciari; G Kieffer; B Bannwarth
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

4.  Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients.

Authors:  M Dupon; G Janvier; G Vinçon; S Winnock; F Demotes-Mainard; O Capeyron; J Saric
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation.

Authors:  Min Kan; Hai-Yan Shi; Zhong-Guo Sui; Wei Zhao; Bing Han; Yue-E Wu; Qian Li; Zi-Xuan Guo; Xue Li; Guo-Xiang Hao; Yi Zheng; Le-Qun Su; Xin Huang
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

6.  There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions.

Authors:  Leslie Z Benet; Jasleen K Sodhi; George Makrygiorgos; Ali Mesbah
Journal:  AAPS J       Date:  2021-05-10       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.